.svg){kind=small}
Mar-2026
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
In Ohio, Farmaceutical Rx (Frx) has shown varied performance across different cannabis categories. In the Edible category, the brand did not make it into the top 30 rankings from December 2025 to March 2026, with its rank fluctuating between 43rd and 57th place. This indicates a challenging market presence for Frx in the Edible segment within Ohio. Conversely, in the Flower category, Frx maintained a more stable position, consistently staying within the top 60, though it did see a dip in February 2026 to 56th place before recovering to 41st in March. This suggests that while the Flower category might be a stronger suit for Frx, there is still room for improvement to secure a more competitive standing.
Examining the sales trends, Farmaceutical Rx (Frx) experienced a significant drop in Edible sales from December 2025 to March 2026, which aligns with its lower rankings in this category. In contrast, the Flower category, despite its fluctuating rank, showed a more resilient sales pattern, with a notable recovery in March 2026 after a dip in February. This resilience in the Flower category could be indicative of a stronger consumer base or effective marketing strategies that are not as apparent in the Edible segment. Such insights underscore the importance of category-specific strategies for Frx to enhance its market presence and capitalize on growth opportunities in Ohio.
Competitive Landscape
In the competitive landscape of the Ohio flower category, Farmaceutical Rx (Frx) has experienced notable fluctuations in its market position over recent months. While Farmaceutical Rx (Frx) did not rank within the top 20 brands, its rank shifted from 39th in December 2025 to 41st by March 2026, with a temporary dip to 56th in February. This indicates a challenging period for the brand, especially when compared to competitors like HillFire, which consistently maintained a higher rank, peaking at 35th in February. Meanwhile, SeCHe showed a steady improvement, surpassing Farmaceutical Rx (Frx) by March with a rank of 40th. Despite these challenges, Farmaceutical Rx (Frx) managed to recover some ground in March, suggesting potential resilience. However, the brand's sales trajectory, which saw a decline from December to February before a slight recovery in March, highlights the need for strategic adjustments to regain competitive positioning against brands like Cheech & Chong's and Wondergrove Cannabis, which have also shown varying performance trends.
Notable Products
In March 2026, GMO Minis (5.66g) emerged as the top-performing product for Farmaceutical Rx (Frx), climbing from its previous absence in the top ranks to first place with notable sales of 1168 units. Banana Kush (2.83g) slipped to second place after leading in January and February, reflecting a decrease in sales momentum. Wedding Cake (2.83g) maintained a steady presence, moving from third in February to third in March as well, indicating consistent demand. Animal Face (2.83g) saw a decline in its ranking, moving from second place in January to fourth in March. Motorbreath #15 (2.83g) entered the top five for the first time, securing the fifth position, suggesting a new interest in this product.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
